EPS for Bellerophon Therapeutics, Inc. (BLPH) Expected At $-0.14; Sarasin & Partners Llp Trimmed Sociedad Quimica Minera De C (SQM) Stake

April 17, 2018 - By Linda Rogers

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Logo

Sarasin & Partners Llp decreased Sociedad Quimica Minera De C (SQM) stake by 60.8% reported in 2017Q4 SEC filing. Sarasin & Partners Llp sold 77,562 shares as Sociedad Quimica Minera De C (SQM)’s stock declined 20.44%. The Sarasin & Partners Llp holds 50,000 shares with $2.97M value, down from 127,562 last quarter. Sociedad Quimica Minera De C now has $14.06 billion valuation. The stock increased 1.81% or $0.95 during the last trading session, reaching $53.41. About 762,692 shares traded. Sociedad Química y Minera de Chile S.A. (NYSE:SQM) has risen 43.96% since April 17, 2017 and is uptrending. It has outperformed by 32.41% the S&P500.

Analysts expect Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) to report $-0.14 EPS on May, 21.They anticipate $0.01 EPS change or 6.67% from last quarter’s $-0.15 EPS. After having $-0.24 EPS previously, Bellerophon Therapeutics, Inc.’s analysts see -41.67% EPS growth. The stock increased 0.49% or $0.01 during the last trading session, reaching $2.07. About 88,098 shares traded. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) has risen 58.74% since April 17, 2017 and is uptrending. It has outperformed by 47.19% the S&P500.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. The company has market cap of $118.75 million. The Company’s product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. It currently has negative earnings.

Sarasin & Partners Llp increased Air Prods & Chems Inc (NYSE:APD) stake by 24,554 shares to 880,851 valued at $144.53M in 2017Q4. It also upped Moodys Corp (NYSE:MCO) stake by 11,292 shares and now owns 268,509 shares. Pfizer Inc (NYSE:PFE) was raised too.

Analysts await Sociedad Química y Minera de Chile S.A. (NYSE:SQM) to report earnings on May, 16. They expect $0.30 EPS, down 23.08% or $0.09 from last year’s $0.39 per share. SQM’s profit will be $78.96 million for 44.51 P/E if the $0.30 EPS becomes a reality. After $0.42 actual EPS reported by Sociedad Química y Minera de Chile S.A. for the previous quarter, Wall Street now forecasts -28.57% negative EPS growth.

Among 10 analysts covering Sociedad Quimica y Minera de Chile (NYSE:SQM), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Sociedad Quimica y Minera de Chile had 30 analyst reports since August 28, 2015 according to SRatingsIntel. The stock of Sociedad Química y Minera de Chile S.A. (NYSE:SQM) earned “Hold” rating by BMO Capital Markets on Thursday, October 5. HSBC downgraded the shares of SQM in report on Wednesday, October 11 to “Reduce” rating. Scotia Capital maintained Sociedad Química y Minera de Chile S.A. (NYSE:SQM) on Thursday, March 1 with “Hold” rating. As per Thursday, July 6, the company rating was maintained by BMO Capital Markets. The company was downgraded on Friday, August 28 by Zacks. The firm has “Buy” rating given on Wednesday, February 7 by J.P. Morgan. The rating was upgraded by Deutsche Bank to “Buy” on Thursday, January 18. The stock of Sociedad Química y Minera de Chile S.A. (NYSE:SQM) has “Hold” rating given on Thursday, January 18 by Scotia Capital. The stock of Sociedad Química y Minera de Chile S.A. (NYSE:SQM) earned “Hold” rating by HSBC on Thursday, March 8. Morgan Stanley downgraded the stock to “Sell” rating in Monday, February 26 report.

Sociedad Química y Minera de Chile S.A. (NYSE:SQM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: